PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

被引：0
|
作者：
Kaplan, Jess
Bousvaros, Athos
Turner, Dan
Dubinsky, Marla C.
Komocsar, Wendy
Larkin, Amy E.
Johns, Jordan
Zhang, Xin
Little, Cheryl A.
Crandall, Wallace
Arora, Vipin
Hyams, Jeffrey S.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
781
引用
收藏
页码：S169 / S169
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [42] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [43] Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE
    Higgins, Peter
    Hebuterne, Xavier
    Siffledeen, Jesse
    Zhou, Wen
    Cataldi, Fabio
    Xie, Wangang
    Lacerda, Ana
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S131 - S131
  • [44] EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: PHASE 3 LUCENT-1 STUDY RESULTS
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    Irving, Peter
    GUT, 2022, 71 : A16 - A17
  • [45] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Watanabe, Mamoru
    Motoya, Satoshi
    Watanabe, Kenji
    Ogata, Haruhiko
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Igeta, Masataka
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
  • [46] Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study
    Sridhar, S.
    Hart, A.
    Venkat, S.
    Huang, K. H. G.
    Yarandi, S.
    Germinaro, M.
    Vetter, M.
    Rubin, D. T.
    Dignass, A.
    Cua, D.
    Freeman, T.
    Waterworth, D.
    Mcrae, B.
    Verstockt, B.
    Branigan, P.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i422 - i422
  • [47] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND
    Schreiber, Stefan
    Panaccione, Remo
    Parkes, Gareth C.
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Hisamatsu, Tadakazu
    Siegmund, Britta
    Kalabic, Jasmina
    Levine, Phillip
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Cheng, Ling
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Louis, Edouard
    GASTROENTEROLOGY, 2024, 166 (05) : S238 - S238
  • [48] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Yao, Xuan
    Ilo, Dapo
    Liu, John
    Hebuterne, Xavier
    Lindsay, James
    Sanchez-Gonzalez, Yuri
    Higgins, Peter D.
    Colombel, Jean-Frederic
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S521 - S522
  • [49] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Long, Millie D.
    Armuzzi, Alessandro
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [50] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    Dhesi, Endip
    GUT, 2023, 72 (SUPPL_2) : A86 - A87
12345